Now or Later? The Role of Neoadjuvant Treatment in Advanced Endometrial Cancer: A Systematic Review.

Endometrial cancer (EC) is, nowadays, the most frequent gynecological malignancy worldwide. The main treatment approach for EC is surgery, especially for early-stage tumors. For advanced EC, chemotherapy (CT) with carboplatin and paclitaxel is the standard treatment, especially for women with metastatic or recurrent disease. The present systematic review aimed to establish whether neoadjuvant treatment regimens with CT and/or radiotherapy (RT) lead to better survival outcomes compared to upfront surgery in advanced EC. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, through the string "(("Endometrial Neoplasms"[Mesh]) AND "Hysterectomy"[Mesh]) AND "Radiotherapy"[Mesh] AND Chemotherapy", the selection of articles was made. A quality assessment was conducted using the Newcastle-Ottawa Scale (NOS). The studies included patients with EC with survival and recurrence outcomes-patients treated with upfront surgery or neoadjuvant CT ± External Beam Radiation Therapy (EBRT) or CT ± Brachytherapy (BT). According to the selected evidence in the scientific literature, the 5-year DFS was 21.3% for upfront surgery and ranged from 42 to 73% for neoadjuvant chemotherapy. Also, the 5-year OS was 6.2 to 49.7% with upfront surgery and 15.5 to 100% for neoadjuvant schemes. None of the studies dedicated to surgery reported the 5-year Recurrence Rate (RR), while in the neoadjuvant treatments, it ranged from 27 to 64.7%. The literature's paucity of data makes it difficult to compare neoadjuvant therapy regimens with upfront surgery in advanced endometrial carcinoma. Nevertheless, the current data show more encouraging results for the neoadjuvant treatment group.